The pharmaceutical landscape is currently witnessing a high-stakes confrontation as Shanghai Henlius Biotech maneuvers to intercept Pfizer’s dominance in the next generation of lung cancer therapy. At the heart of this struggle is the development of antibody-drug conjugates (ADCs) targeting PD-L1,
Lukas Hainz sits down with Ivan Kairatov, a distinguished biopharma expert with a deep background in research and development and a keen eye for technological innovation within the pharmaceutical industry. Together, they explore a recent breakthrough from the University of Cambridge that reimagines
The global pharmaceutical landscape is currently navigating a period of intense pressure as the rise of multi-drug resistant pathogens outpaces the traditional speed of antibiotic development. For decades, the process of vetting new chemical entities has been a fragmented journey, requiring
The relentless pursuit of highly effective oncological interventions has historically been hampered by the inability of traditional pharmaceutical agents to distinguish accurately between malignant cells and healthy physiological structures. While chemotherapy and systemic radiation have saved
The silent progression of osteosarcoma remains one of the most daunting challenges in modern pediatric oncology, often remaining undetected until the malignancy has already begun its journey to distant organs. While medical science has mastered the art of treating localized bone tumors through a
The human cell operates as a high-speed logistics hub where the physical location of cargo determines the fate of the entire biological operation. For decades, biology textbooks have described lysosomes as simple waste disposal units—tiny acidic balloons drifting through the cytoplasm to dissolve
